Anti-PHGDH antibodies are immunoglobulins that specifically recognize and bind PHGDH, the gene encoding D-3-phosphoglycerate dehydrogenase in humans. In research applications, these antibodies are used to detect PHGDH in tissue samples, cell lysates, and cultured cells. PHGDH catalyzes the first committed step of the phosphorylated serine biosynthesis pathway, oxidizing 3-phospho-D-glycerate to initiate serine production from glycolytic intermediates. Because PHGDH-driven serine synthesis supports nucleotide and redox metabolism in rapidly dividing cells, it is a prominent target in cancer metabolism research.
Catalog highlights and purchasing considerations
About the Biocompare PHGDH antibody catalog
The Biocompare antibody search tool lists PHGDH antibodies from a wide range of suppliers, with immunohistochemistry, western blot, and immunofluorescence among the most common validated applications. Listings may also appear under the earlier name 3-PGDH, reflecting the enzyme's alternate abbreviation. Several PHGDH antibodies mentioned here have been cited across a range of cancer metabolism research, including studies on PHGDH restricting viral replication by sustaining antioxidant capacity, PHGDH loss promoting hypoxia tolerance through glycolytic reprogramming, and PHGDH's noncanonical role in driving PD-L1 expression and cancer immune evasion.
Considerations when choosing a PHGDH antibody for research
Confirm that the antibody's intended target is accurate, as many genes carry synonym symbols that can create ambiguity across suppliers. Specificity should be verified against the immunogen sequence or region listed on the product datasheet, since antibodies raised against different epitopes of the same protein can behave differently across applications. Beyond specificity, several target-related attributes can affect antibody binding, including subcellular location, extracellular and cytoplasmic domain boundaries for membrane-associated targets, tissue specificity, post-translational modifications, and the presence of additional isoforms or disease-associated variants. In parallel, antibody-specific selection criteria warrant consideration, including clonality (monoclonal versus polyclonal), host species, species reactivity, and conjugate or label choice suited to the detection method. Supplier validation data, such as western blot bands at the expected molecular weight, immunohistochemistry staining patterns consistent with known tissue distribution, and knockout or knockdown controls, should also be carefully reviewed before purchase.